Download PDF
Thromb Haemost 1997; 78(06): 1434-1437
DOI: 10.1055/s-0038-1665429
Rapid Communication
Schattauer GmbH Stuttgart

Platelet Activation Markers in Patients with Peripheral Arterial Disease

A Prospective Comparison of Different Platelet Function Tests
Paolo Gresele
1   Institute of Internal Medicine and Vascular Medicine, University of Perugia, Italy
,
Mariella Catalano
2   The Department of Medicine, University of Milano, Italy
,
Carlo Giammarresi
3   The Department of Medicine, University of Chieti, Italy
,
Raul Volpato
1   Institute of Internal Medicine and Vascular Medicine, University of Perugia, Italy
,
Rosanna Termini
3   The Department of Medicine, University of Chieti, Italy
,
Giovanni Ciabattoni
4   Institute of Pharmacology, Catholic University of Rome, Italy
,
Giuseppe G Nenci
1   Institute of Internal Medicine and Vascular Medicine, University of Perugia, Italy
,
Giovanni Davì
3   The Department of Medicine, University of Chieti, Italy
› Author Affiliations
Further Information

Publication History

Received 20 1997

Accepted after resubmission 18 June 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Peripheral vascular disease (PVD) is an indicator of diffuse atherosclerosis and is associated with a greatly increased incidence of coronary heart and cerebrovascular disease. Although several studies have assessed whether in vivo platelet activation takes place in patients with PVD, no data are available comparing different platelet function tests in this patient population.

We have compared prospectively four tests for the measurement of in vivo platelet activation (plasma βTG, plasma PF4, intraplatelet (βTG and urinary excretion of 11-dehydro-TXB2) and one in vitro platelet function test (ADP-induced platelet aggregation) in 63 well-characterized patients with intermittent claudication and in 18 age- and sex- matched healthy volunteers.

No statistically significant difference was found between patients and controls for plasma βTG (20.0 ± 11.8 vs. 18.8 ± 9.0 ng/ml, respectively), plasma PF4 (5.2 ± 2.9 vs. 6.3 ± 3.5 ng/ml), βTG/PF4 ratio (4.0 ± 2.9 vs. 3.6 ± 1.8), intraplatelet pTG (4503 ± 1482 vs. 4059 ± 1065 ng/ml), and threshold aggregatory concentration of ADP (1.7 ± 0.72 vs. 1.45 ± 0.56 μM).

Urinary 11-dehydro-TXB2 was instead significantly higher in the PVD group (55.4 ± 27.5 vs. 26.7 ± 7.0 ng/h, p <0.001).

Our study shows that urinary 11-dehydro-TXB2 is a more sensitive index of in vivo platelet activation than the measurement of either platelet specific proteins or of in vitro platelet aggregation in patients with PVD.

 

  • References

  • 1 Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386
    CrossrefPubMedGoogle Scholar
  • 2 Ross R. The pathogenesis of atherosclerosis. In: Heart Disease. Braun wald. ed. Philadelphia: Saunders; 1988: 35-52
    Google Scholar
  • 3 Ward AS, Porter N, Preston FE, Morris JonesW. Platelet aggregation in patients with peripheral vascular disease. Atherosclerosis 1978; 29: 63-68
    CrossrefPubMedGoogle Scholar
  • 4 Celia G, Zahavi J, de Haas HA, Kakkar VV. Betathromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979; 43: 127-136
    CrossrefPubMedGoogle Scholar
  • 5 Kaplan KL, Owen J. Plasma levels of -p and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
    PubMedGoogle Scholar
  • 6 The Pack Trial Group. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multicenter doubleblind, placebo controlled trial. Thromb Res 1989; 55: 13-23
    CrossrefPubMedGoogle Scholar
  • 7 Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 1988; 50: 377-386
    CrossrefPubMedGoogle Scholar
  • 8 O’Brien JR, Etherington MD. Platelet α-granule proteins in stroke and transient ischemic attacks. Lancet 1984; 1: 231-232
    PubMedGoogle Scholar
  • 9 Carlsson I, Benthin G, Petersson A, Wennmalm A. Differential inhibition of thromboxane A2 and prostacyclin synthesis by low dose acetylsalicylic acid in atherosclerotic patients. Thromb Res 1990; 57: 437-444
    CrossrefPubMedGoogle Scholar
  • 10 Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962; 27: 117-126
    PubMedGoogle Scholar
  • 11 Davì G, Rini GB, Di Avema M, Fede G, Novo S, Notarbartolo A, Strano A. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb Res 1982; 26: 359-370
    CrossrefPubMedGoogle Scholar
  • 12 Gresele P, Amout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-1445
    CrossrefPubMedGoogle Scholar
  • 13 Gresele P, Dottorini M, Selli ML, Iannacci L, Canino S, Todisco T, Romano S, Crook P, Page CP, Nenci GG. Altered platelet function associated with the bronchial hyperesponsiveness accompanying nocturnal asthma. J All Clin Immunol 1993; 91: 894-902
    CrossrefPubMedGoogle Scholar
  • 14 Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
    CrossrefPubMedGoogle Scholar
  • 15 CAPRIE Steering Committee. A randomized blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
    CrossrefPubMedGoogle Scholar
  • 16 D’Souza D, Wu KK, Heliums JD, Phillips MD. Platelet activation and arterial thrombosis. Lancet 1994; 344: 991-995
    CrossrefPubMedGoogle Scholar
  • 17 Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996; 239: 17-34
    CrossrefPubMedGoogle Scholar
  • 18 Patrono C, Davì G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med 1992; 2: 15-20
    CrossrefPubMedGoogle Scholar
  • 19 Reilly IAG, Doran JB, Smith B, FitzGerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300-1309
    CrossrefPubMedGoogle Scholar
  • 20 Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Bom GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63: 163-168
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
    CrossrefPubMedGoogle Scholar
  • 22 Sinzinger H, Virgolini I, Fitscha P. Platelet kinetics in patients with atherosclerosis. Thromb Res 1990; 57: 507-516
    CrossrefPubMedGoogle Scholar
  • 23 Nenci GG, Gresele P, Agnelli G, Parise P. Intrinsically defective or exhausted platelets in hairy cell leukemia?. Thromb Haemost 1981; 46: 572
    Article in Thieme ConnectPubMedGoogle Scholar